TABLE 4.
Percentages of AVEG 201 adult vaccine recipients with detectable HIV Env-specific IgA
| HIV antigen | Recipients (%)a |
|||||
|---|---|---|---|---|---|---|
| Placebo (n = 10) |
Chiron (n = 42) |
VaxGen (n = 49) |
||||
| Visit 2 | Visit 11 | Visit 2 | Visit 11 | Visit 2 | Visit 11 | |
| A1 con gp140 | 0 | 0 | 0 | 2 | 0 | 4 |
| B con gp140 | 0 | 0 | 0 | 14 | 2 | 22 |
| C1 peptide | 0 | 0 | 0 | 7 | 6 | 6 |
| MN gp120 | 0 | 0 | 0 | 19 | 2 | 8 |
Visit 2 was preimmunization, and visit 11 took place 2 weeks after the last vaccine dose.